Stability of a trivalent recombinant protein vaccine formulation against botulinum neurotoxin during storage in aqueous solution

Journal of Pharmaceutical Sciences

Volumn 98, Issue 9, 2009, Pages 2970-2993

  Vessely, Christina ^a   Estey, Tia ^a   Randolph, Theodore W ^b   Henderson, Ian ^c   Cooper, Julianne ^d   Nayar, Rajiv ^d   Braun, Latoya Jones ^a   Carpenter, John F ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UCB 450   (United States)

^c A CSC Company   (United States)

^d HTD Biosystems   (United States)

Author keywords

Aluminum salt adjuvant; Botulinum neurotoxin; Competitive adsorption; Recombinant vaccine; Stability; Trivalent vaccine

Indexed keywords

BOTULINUM TOXIN; RECOMBINANT ANTIGEN; RECOMBINANT PROTEIN; RECOMBINANT VACCINE;

AQUEOUS SOLUTION; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG SOLUTION; DRUG STABILITY; DRUG STORAGE; FLUORESCENCE SPECTROSCOPY; ULTRAVIOLET SPECTROSCOPY;

EID: 68949113643     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21498     Document Type: Article

References (40)

1. Yang G, Kim K, Jeong S, Huh G, Kim J, Jungh H. 2004. Isolation and characterization of a neutralizing antibody specific to internalization domain of Clostridium botulinum neurotoxin type B. Toxicon 44:19-25. (Pubitemid 38844238)
2. Cherington M. 1998. Clinical spectrum of botulism. Muscle Nerve 21:701-710.
3. Comella C, Pullman S. 2004. Botulinum toxins in neurological disease. Muscle Nerve 29:628-644.
4. Turton K, Chaddock J, Acharya K. 2002. Botulinum and tetanus neurotoxins: Structure, function and therapeutic utility. Trends Biochem Sci 27:552-558. (Pubitemid 35335403)
5. Cochrane R. 1947. History of the Chemical Warfare Service in World War II (1July 1940-15 August 1945). Historical Section, Plans, Training and Intelligence Division, Office of Chief, Chemical Corps, United States Army. Biological Warfare Research in the United States; Vol II, ed., Fort Detrick, MD.
6. Arnon S, Schechter R, Inglesby T, Henderson D, Bartlett J, Ascher M, Eitzen E, Fine A, Hauer J, Layton M, Lillibridge S, Osterholm M, O'toole T, Parker G, Perl T, Russell P, Swerdlow D, Tonat T. 2001. Botulinum Toxin as a Biological Weapon - Medical and Public Health Management. JAMA 285:1059-1070.
7. Lamb A. 2001. Biological weapons: The facts not the fiction. Clin Med 1:502-504.
8. DePaz RA, Henderson I, Advant S. 2005. Formulation of botulinum neurotoxin heavy chain fragments for vaccine development: Mechanisms of adsorption to an aluminum-containing adjuvant. Vaccine 23:4029-4035. (Pubitemid 40800663)
9. Byrne M, Smith L. 2000. Development of vaccines for prevention of botulism. Biochimie 82:955-966.
10. O'Hagan D, MacKichan M, Singh M. 2001. Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng 18:69-85. (Pubitemid 32889607)
11. Singh M, O'Hagan D. 1999. Advances in vaccine adjuvants. Nat Biotechnol 17:1075-1081.
12. Rinella J, Workman R, Hermodson M, White J, Hem S. 1998. Elutability of proteins from aluminum-containing vaccine adjuvants by treatment with surfactants. J Colloid Interface Sci 197:48-56. (Pubitemid 28383532)
13. Jendrick S, Little S, Hem S, Mitra G, DGiardina S. 2003. Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants. Vaccine 21:3011-3018. (Pubitemid 36703210)
14. Vessely C, Estey T, Randolph T, Henderson I, Nayar R, Carpenter JF. 2007. Effects of solution conditions and surface chemistry on the adsorption of three recombinant botulinum neurotoxin antigens to aluminum salt adjuvants. J Pharm Sci 96:2375-2389. (Pubitemid 47477893)
15. Eldridge J, Staas J, Mueulbroek A, Tice T, Gilley R. 1991. Biodegradable and biocompatible poly(DL-Lactide-Co-Glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun 59:2978-2986.
16. Gupta R, Rost B, Releveld E, Siber G. 1995. Adjuvant properties of aluminum and calcium compounds. In: Powell M, Newman M, editors. Pharmaceutical biotechnology. editors. New York: Plenum Press. pp. 229-248.
17. Lenk T, Horbett T, Ratner B. 1991. Infrared spectroscopic studies of time-dependent changes in fibrinogen adsorbed to polyurethanes. Langmuir 7:1755-1764. (Pubitemid 21737595)
18. Ta T, McDermott M. 2000. Mapping interfacial chemistry induced variations in protein adsorption with scanning force microscopy. Anal Chem 72:2627-2634. (Pubitemid 30395673)
19. Van Tassel P, Guemouli L, Ramsden J, Tarjus G, Viot P, Talbot J. 1998. A particle-level model of irreversible protein adsorption with a post adsorption transition. J Colloid Interface Sci 207:317-323. (Pubitemid 28523156)
20. Randolph T, Jones L. 2002. Surfactant-protein interactions. In: Carpenter J, Manning M, editors. Rational design of stable protein formulations: Theory and practice. editors. New York: Plenum Press. pp. 159-175.
21. Norde W, Giacomelli C. 2000. BSA structural changes during homomolecular exchange between the adsorbed and the dissolved states. J Biotechnol 79:259-268. (Pubitemid 30365198)
22. Norde W, Lyklema J. 1991. Why proteins prefer interfaces. J Biomater Sci Polym Ed 2:183-202.
23. Estey T, Vessely C, Randolph T, Henderson I, Jones L, Nayar R, Carpenter JF. The chemical degradation of a trivalent recombinant protein vaccine against botulinum neurotoxin by LysC peptide mapping and MALDI-TOF mass spectrometry. J Pharm Sci (in press).
24. Ragone R, Colonna G, Balestrieri C, Servillo L, Irace G. 1984. Determination of tyrosine exposures in proteins by second-derivative spectroscopy. Biochemistry 23:1871-1875.
25. Rinella J, White J, Hem S. 1995. Effect of anions on model aluminum-adjuvant-containing vaccines. J Colloid Interface Sci 172:121-130.
26. Jones L, Peek L, Power J, Markham A, Yazzie B, Middaugh C. 2005. Effects of adsorption to aluminum salt adjuvants on the structure and stability of model proteins. J Biol Chem 280:13406-13414. (Pubitemid 40517228)
27. Kueltzo L, Ersoy B, Ralston J, Middaugh C. 2003. Derivative absorbance spectroscopy and protein phase diagrams as tools for comprehensive protein characterization: A bGCSF Case Study. J Pharm Sci 92:1805-1820. (Pubitemid 37071814)
28. Wendorf J, Radke C, Blanch H. 2004. Reduced protein adsorption at solid interfaces by sugar excipients. Biotechnol Bioeng 87:565-573. (Pubitemid 39295401)
29. Rinella J, Workman R, Hermodson M, White J, Hem S. 1998. Elutability of proteins from aluminum-containing vaccine adjuvants by treatment with surfactant. J Colloid Interface Sci 197:48-56. (Pubitemid 28383532)
30. Arnebrant T, Wahlgren M. 1995. Protein surfactant interactions at solid surfaces. In: Horbett T, JL B, editors. Proteins at interfaces II: Fundamentals and applications. editors. Washington DC: Americal Chemical Society. pp. 239-255.
31. McGuire J, Wahlgren M, Arnebrant T. 1995. Structural stability effects on the adsorption and dodecyltrimethylammonium bromide-mediated elutability of bacteriophage T4 lysozyme at silica surfaces. J Colloid Interface Sci 170:182-192.
32. Shi Y, HogenEsch H, Hem S. 2002. Change in the degree of adsorption of proteins by aluminium - Containing adjuvants following exposure to interstitial fluid: Freshly prepared and aged model vaccines. Vaccine 20:80-85. (Pubitemid 32905317)
33. McNay J, Fernandez E. 2001. Protein unfolding during reversed phase chromatography: I. Effect of surface properties and duration of adsorption. Biotechnol Bioeng 76:224-232.
34. Morefield G, Jiang D, Romero-Mendez I, Geahlen R, HogenEsch H, Hem S. 2005. Effect of phosphorylation of ovalbumin on adsorption by aluminum containing adjuvants and elution upon exposure to interstitial fluid. Vaccine 23:1502-1506. (Pubitemid 40164710)
35. Iyer S, HogenEsch H, Hem S. 2003. Relationship between the degree of antigen adsorption of aluminum hydroxide adjuvant in interstitial fluid and antibody production. Vaccine 21:1219-1223. (Pubitemid 36139952)
36. Lenk J, Ratner B, Gendreau R, Chittur K. 1989. IR spectral changes of bovine serum albumin upon surface adsorption. J Biomed Mater Res 23:549-569. (Pubitemid 19137339)
37. Caessens P, de Jongh H, Norde W, Gruppen H. 1999. The adsorption-induced secondary structure of β-casein and of distinct parts of its sequence in relation to foam and emulsion properties. Biochim Biophys Acta 1430:73-83. (Pubitemid 29132836)
38. Remmele RL, Nightlinger N, Srinivasan S, Gombotz W. 1998. Interleukin-1 receptor (IL-1R) liquid formulation development using differential scanning calorimetry. Pharm Res 15:200-208. (Pubitemid 28144230)
39. Daly S, Przybycien T, Tilton R. 2003. Coverage-dependent orientation of lysozyme adsorbed on silica. Langmuir 19:3848-3857.
40. Daly S, Przybycien T, Tilton R. 2005. Adsorption of poly(ethylene glycol)-modified lysozyme to silica. Langmuir 21:1328-1337. (Pubitemid 40275069)